Cargando…
Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model
To date, two published randomized trials have indicated a clinical benefit of early treatment with fluvoxamine versus placebo for adults with symptomatic COVID-19. Using the results of the largest of these trials, the TOGETHER trial, we conducted a cost–consequence analysis to assess the health syst...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Tropical Medicine and Hygiene
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833089/ https://www.ncbi.nlm.nih.gov/pubmed/36379209 http://dx.doi.org/10.4269/ajtmh.22-0106 |